Enveric Biosciences的Zacks评级 - Enveric Biosciences最近被升级为Zacks Rank 1 (Strong Buy)[1] - Zacks评级系统的升级对Enveric Biosciences的盈利前景表示乐观，可能对其股价产生积极影响[4] - Enveric Biosciences的盈利预期持续上升，这意味着公司基本业务的改善，投资者对这种趋势的认可可能推动股价上涨[6] - Enveric Biosciences的Zacks Rank 1升级使其在盈利预期修订方面位于Zacks覆盖股票的前5%，暗示该股可能在近期上涨[13] Zacks评级系统 - Zacks评级系统主要跟踪卖方分析师对公司当前和未来年度盈利预期的共识估计[2] - Zacks评级系统有效利用盈利预期修订的力量，与盈利预期修订趋势和股价近期波动之间存在强相关性[7] - Zacks评级系统将股票分为五组，从Zacks Rank 1 (Strong Buy)到Zacks Rank 5 (Strong Sell)，Zacks Rank 1的股票自1988年以来平均年回报率为+25%[8] - Zacks评级系统保持对超过4000只股票的'买入'和'卖出'评级的平等比例，只有Zacks覆盖的前5%的股票获得'Strong Buy'评级，而接下来的15%获得'Buy'评级[11] Enveric Biosciences的盈利预期 - Enveric Biosciences预计2024年12月的每股收益为-1.98美元，同比增长75.3%[9] - 过去三个月，分析师一直在提高对Enveric Biosciences的盈利预期，Zacks共识估计增长了42.6%[10]

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Zuora, Inc. (ZUO) : This enterprise software company that creates and provides software for businesses to launch and manage their subscription-based services has seen the Zacks Consensus Estimate for its current year earnings increasing 28.1% over the last 60 days.Intrusion Inc. (INTZ) : This cybersecurity company based in the United States has seen the Zacks Consensus Estimate for its current year earnings increasing 65.6% over the las ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 26, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Nap ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___ to ___ Commission File Number 001-38286 ENVERIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4484725 (State or other jurisdicti ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that it has signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applicatio ...

Enveric Biosciences专利新闻 - Enveric Biosciences（NASDAQ: ENVB）宣布美国专利局颁发了两项专利，分别是“多取代革兰氏菌素衍生物”和“硝化革兰氏菌素衍生物”[1] - 这两项专利覆盖了许多潜在药物候选物质，包括与未透露的六种化合物相关的三份最近宣布的非约束性期限表[2] - Enveric的首席执行官Joseph Tucker博士表示，这些新专利扩展了公司的专利组合，为当前和未来的合作伙伴和许可证持有人提供了更多机会，强调了PsybraryTM收藏的其他分子的专利覆盖范围[3]

Biotech investors know that small companies can make massive moves on big headlines, and we’re seeing such a move in Enveric Biosciences (NASDAQ:ENVB) today. Shares of ENVB stock are up more than 120% in early afternoon trading today after the company put forward a press release highlighting plans to license three classes of its compounds.This little-known biotech stock is one that’s garnering attention around this deal as Enveric looks to out-license three classes of its compounds. The company currently ha ...

Enveric Biosciences公司的专利组合 - Enveric Biosciences公司出售了与癌症相关的专利组合[2] Enveric Biosciences公司的神经可塑性化合物 - Enveric Biosciences公司揭示了多种新型神经可塑性化合物[3] Enveric Biosciences公司的研究重点 - Enveric Biosciences公司的研究重点是神经可塑性疗法的发展[15]

Enveric Biosciences专利出售 - Enveric Biosciences（NASDAQ: ENVB）宣布出售其与癌症相关的专利组合[1] - 出售的专利涵盖了大麻二酚和第二治疗剂的协同组合用于治疗癌症[2] - Enveric将不再拥有出售的专利组合的所有权[3] Enveric的发展计划 - Enveric计划继续专注于开发其主力候选药物EB-003和EB-002，前者是一种首创的神经可塑性药物，旨在消除幻觉，后者是活性代谢物哌啶的下一代合成前药[1] 专利出售的影响 - 出售专利组合将为Enveric提供机会，继续专注于开发神经可塑性药物，同时为购买者提供基础专利保护，预计购买者将开展研究、临床试验和商业开发，以治疗特定类型的癌症[4]

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the discovery of multiple, promising novel compounds sourced using the company’s Psybrary™ platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (PsyAI™). The novel compoun ...